LISTED Australian life sciences and medicinal cannabis company, Medlab Clinical is expanding its international distribution opportunities by executing a Heads of Agreement with Thai-listed pharmaceutical company, Mega Lifesciences Public Company Limited.
Mega Lifesciences has a presence in 33 countries around the world.
Medlab signed a similar agreement with Canadian generic pharmaceutical company, Pharmascience in Mar this year.
Both deals focus initially on Medlab's NanaBis, a nano-delivered form of cannabis, which is at the second stage of a clinical trial at Royal North Shore Hospital, where it is being used for pain management with seriously ill cancer patients.
NanaBis is delivered by a back of the cheek spray by Nanocelle, which facilitates buccal absorption.
The product is already available via the Australian Government's Special Access Scheme and is currently before several regulatory agencies for potential fast track drug approval pathways, the company says.
Medlab CEO, Dr Sean Hall, said, "NanaBis is in an exciting stage of its development as the Company looks to fast track global drug approval pathways.
"This Heads of Agreement signifies real intent and interest for a true global pharmaceutical company to enter legitimate science as it relates to cannabis that has been research focused into a serious condition: cancer pain."
The above article was sent to subscribers in Pharmacy Daily's issue from 29 May 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 May 19
